Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes

Diabetes Clinical Trial

Official title:

Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04113694
• Other study ID #: CEP298
• Status: Completed
• Phase: N/A
• Start date: October 14, 2019
• Est. completion date: November 5, 2020

Study information

• Verified date: September 2021
• Source: Medtronic Diabetes
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to collect confirmatory clinical data to support 6 or 7 days wear of EWIS (Extended Wear Infusion Set).

Description:

This study is a multi-center, non-randomized, prospective single arm study with Type 1 patients with diabetes on insulin pump therapy with Continuous Glucose Monitoring (CGM). A total of up to 300 subjects age 18-80 will be enrolled at up to 20 investigational centers in the US. Each subject will wear their own MiniMed™ 670G insulin system. Each subject will be given 12 infusion sets to wear (each infusion set for at least 174 hours, or until infusion set failure if this occurs before 174 hours). Subjects will change insulin reservoirs at least every 174 hours. The time of infusion set insertion will be taken from Daily Log. Subjects can expect to participate for approximately 12-16 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 291
• Est. completion date: November 5, 2020
• Est. primary completion date: November 5, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Subject is age 18 - 80 years at the time of screening

2. Subject has type 1 diabetes for more than one year Study specific inclusion criteria

3. Subject is on the MiniMed™ 670G insulin pump therapy within 1 year prior to screening and willing to utilize Auto Mode and CGM with Guardian™ Sensor (3) during the study.

4. Subject is willing and able to perform study procedures as per investigator discretion

5. Subject is willing to take one of the following insulins and can financially support the use of either of the 2 insulin preparations throughout the course of the study (i.e. co-payments for insulin with insurance or able to pay full amount):

1. Humalog™* (insulin lispro injection)

2. NovoLog™* (insulin aspart)

Exclusion Criteria:

1. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks.

2. Subject is female and has a positive pregnancy screening test

3. Subject is female of child bearing age and who is sexually active should be excluded if she is not using a form of contraception deemed reliable by investigator

4. Subject is female and plans to become pregnant during the course of the study

5. Subject has Glycosylated hemoglobin (HbA1c) > 8.5 % at time of screening. Note: All HbA1c blood specimens will be sent to and tested by a NGSP certified Central Laboratory. HbA1c testing must follow National Glycohemoglobin Standardization Program (NGSP) standards.

6. Subject has had a history of 1 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening

1. Medical assistance (i.e. Paramedics, Emergency Room [ER] or Hospitalization)

2. Coma

3. Seizures

7. Subject has taken any oral, injectable, or IV glucocorticoids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study.

8. Subject is unable to tolerate tape adhesive in the area of infusion set

9. Subject has any unresolved adverse skin condition in the area of infusion set placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)

10. Subject has infection in the area of infusion set placement at time of screening

11. Subject has had Diabetic Ketoacidosis (DKA) in the 12 months prior to screening visit.

12. Subject is currently abusing illicit drugs

13. Subject is currently abusing alcohol

14. Subject is on dialysis (for renal failure)

15. Subject has history of adrenal disorder

16. Subject has a history of inpatient psychiatric treatment in the past 6 months prior to screening

17. Subject has any condition that the Investigator believes would interfere with study participation

18. Subject has a history of visual impairment which would not allow subject to participate in the study and perform all study procedures safely, as determined by the investigator

19. Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening

20. Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation

21. Subject is using pramlintide (Symlin), SGLT2 inhibitors, GLP agonists, biguanides, DPP-4 inhibitors or sulfonylureas more than 2 weeks from time of screening

22. Subject has been diagnosed with chronic kidney disease requiring dialysis or resulting in chronic anemia

23. Subject has history of cardiovascular disease defined as any ischemic related event or clinically significant arrythmia.

24. Subject has hypothyroidism and has out of reference range thyroid-stimulating hormone (TSH) on screening visit (prior labs in the last 3 months are sufficient). Subject may repeat TSH draw to verify eligibility if not in range

Related Conditions & MeSH terms

• Diabetes
• Diabetes Mellitus

Intervention

Device:
• Extended Infusion Set
Each subject is asked to wear each Extended Wear Infusion Set for at least 174 hours.

Locations

Country	Name	City	State
United States	Atlanta Diabetes Associates	Atlanta	Georgia
United States	Barbara Davis Center for Childhood Diabetes	Aurora	Colorado
United States	Grunberger Diabetes Institute	Bloomfield Hills	Michigan
United States	University of Virginia Health System	Charlottesville	Virginia
United States	AMCR Institute	Escondido	California
United States	Diabetes and Endocrinology Consultants of Pennsylvania	Feasterville-Trevose	Pennsylvania
United States	Medical Investigations	Little Rock	Arkansas
United States	AM Diabetes and Endocrinology Center	Memphis	Tennessee
United States	Stanford University	Palo Alto	California
United States	Rainier Clinical Research Center	Renton	Washington
United States	Mayo Clinic (Rochester MN)	Rochester	Minnesota
United States	Endocrine Research Solutions	Roswell	Georgia
United States	SoCal Diabetes	West Covina	California
United States	Iowa Diabetes and Endocrinology Center	West Des Moines	Iowa
United States	Metabolic Research Institute	West Palm Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic Diabetes

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Humalog Subjects - Rate of Infusion Set Failure at the End of Day 6	Evaluate rate of infusion set failure due to unexplained hyperglycemia (i.e. suspected occlusion) at the end of Day 6.	144 hours
Primary	Novolog Subjects - Rate of Infusion Set Failure at the End of Day 6	Independently evaluate rate of infusion set failure due to unexplained hyperglycemia (i.e. suspected occlusion) at the end of Day 6.	144 hours
Secondary	Humalog Subject - Rate of Infusion Set Failure at the End of Day 7.	Evaluate rate of infusion set failure due to unexplained hyperglycemia (i.e. suspected occlusion) at the end of Day 7.	168 hours
Secondary	Novolog Subjects - Rate of Infusion Set Failure at the End of Day 7.	Independently evaluated rate of infusion set failure due to unexplained hyperglycemia (i.e. suspected occlusion) at the end of Day 7.	168 hours